Matches in SemOpenAlex for { <https://semopenalex.org/work/W4311573313> ?p ?o ?g. }
- W4311573313 endingPage "e0271145" @default.
- W4311573313 startingPage "e0271145" @default.
- W4311573313 abstract "Chronic hepatitis B (CHB) is a global health care challenge and a major cause of liver disease. To find new therapeutic avenues with a potential to functionally cure chronic Hepatitis B virus (HBV) infection, we performed a focused screen of epigenetic modifiers to identify potential inhibitors of replication or gene expression. From this work we identified isonicotinic acid inhibitors of the histone lysine demethylase 5 (KDM5) with potent anti-HBV activity. To enhance the cellular permeability and liver accumulation of the most potent KDM5 inhibitor identified (GS-080) an ester prodrug was developed (GS-5801) that resulted in improved bioavailability and liver exposure as well as an increased H3K4me3:H3 ratio on chromatin. GS-5801 treatment of HBV-infected primary human hepatocytes reduced the levels of HBV RNA, DNA and antigen. Evaluation of GS-5801 antiviral activity in a humanized mouse model of HBV infection, however, did not result in antiviral efficacy, despite achieving pharmacodynamic levels of H3K4me3:H3 predicted to be efficacious from the in vitro model. Here we discuss potential reasons for the disconnect between in vitro and in vivo efficacy, which highlight the translational difficulties of epigenetic targets for viral diseases." @default.
- W4311573313 created "2022-12-27" @default.
- W4311573313 creator A5001175580 @default.
- W4311573313 creator A5002409090 @default.
- W4311573313 creator A5012251433 @default.
- W4311573313 creator A5012991703 @default.
- W4311573313 creator A5016008299 @default.
- W4311573313 creator A5016159747 @default.
- W4311573313 creator A5019519252 @default.
- W4311573313 creator A5021921986 @default.
- W4311573313 creator A5023626856 @default.
- W4311573313 creator A5025354639 @default.
- W4311573313 creator A5027475930 @default.
- W4311573313 creator A5037703797 @default.
- W4311573313 creator A5039359774 @default.
- W4311573313 creator A5046334669 @default.
- W4311573313 creator A5051316642 @default.
- W4311573313 creator A5052749295 @default.
- W4311573313 creator A5055173079 @default.
- W4311573313 creator A5063498287 @default.
- W4311573313 creator A5065508092 @default.
- W4311573313 creator A5067029963 @default.
- W4311573313 creator A5068133635 @default.
- W4311573313 creator A5069419034 @default.
- W4311573313 creator A5076990565 @default.
- W4311573313 creator A5078583145 @default.
- W4311573313 creator A5087651718 @default.
- W4311573313 creator A5087813809 @default.
- W4311573313 creator A5088620759 @default.
- W4311573313 date "2022-12-07" @default.
- W4311573313 modified "2023-10-06" @default.
- W4311573313 title "Characterization of a KDM5 small molecule inhibitor with antiviral activity against hepatitis B virus" @default.
- W4311573313 cites W1676377504 @default.
- W4311573313 cites W1799522345 @default.
- W4311573313 cites W1844576826 @default.
- W4311573313 cites W1906916220 @default.
- W4311573313 cites W1982409009 @default.
- W4311573313 cites W1991040699 @default.
- W4311573313 cites W2003692477 @default.
- W4311573313 cites W2006618903 @default.
- W4311573313 cites W2018707079 @default.
- W4311573313 cites W2022672498 @default.
- W4311573313 cites W2022936129 @default.
- W4311573313 cites W2032736838 @default.
- W4311573313 cites W2035509260 @default.
- W4311573313 cites W2053516224 @default.
- W4311573313 cites W2059255388 @default.
- W4311573313 cites W2069841786 @default.
- W4311573313 cites W2072016709 @default.
- W4311573313 cites W2076192079 @default.
- W4311573313 cites W2078828237 @default.
- W4311573313 cites W2079006974 @default.
- W4311573313 cites W2086342381 @default.
- W4311573313 cites W2103377484 @default.
- W4311573313 cites W2107277218 @default.
- W4311573313 cites W2114104545 @default.
- W4311573313 cites W2118365585 @default.
- W4311573313 cites W2120100277 @default.
- W4311573313 cites W2125065061 @default.
- W4311573313 cites W2127835459 @default.
- W4311573313 cites W2133717458 @default.
- W4311573313 cites W2137526110 @default.
- W4311573313 cites W2139008292 @default.
- W4311573313 cites W2143233396 @default.
- W4311573313 cites W2147084784 @default.
- W4311573313 cites W2167315449 @default.
- W4311573313 cites W2168602111 @default.
- W4311573313 cites W2169456326 @default.
- W4311573313 cites W2192080449 @default.
- W4311573313 cites W2211837538 @default.
- W4311573313 cites W2221555640 @default.
- W4311573313 cites W2298466016 @default.
- W4311573313 cites W2408049103 @default.
- W4311573313 cites W2463708289 @default.
- W4311573313 cites W2528277687 @default.
- W4311573313 cites W2577159120 @default.
- W4311573313 cites W2952107284 @default.
- W4311573313 cites W3132711995 @default.
- W4311573313 cites W4221122570 @default.
- W4311573313 cites W647519093 @default.
- W4311573313 doi "https://doi.org/10.1371/journal.pone.0271145" @default.
- W4311573313 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36477212" @default.
- W4311573313 hasPublicationYear "2022" @default.
- W4311573313 type Work @default.
- W4311573313 citedByCount "1" @default.
- W4311573313 countsByYear W43115733132023 @default.
- W4311573313 crossrefType "journal-article" @default.
- W4311573313 hasAuthorship W4311573313A5001175580 @default.
- W4311573313 hasAuthorship W4311573313A5002409090 @default.
- W4311573313 hasAuthorship W4311573313A5012251433 @default.
- W4311573313 hasAuthorship W4311573313A5012991703 @default.
- W4311573313 hasAuthorship W4311573313A5016008299 @default.
- W4311573313 hasAuthorship W4311573313A5016159747 @default.
- W4311573313 hasAuthorship W4311573313A5019519252 @default.
- W4311573313 hasAuthorship W4311573313A5021921986 @default.
- W4311573313 hasAuthorship W4311573313A5023626856 @default.
- W4311573313 hasAuthorship W4311573313A5025354639 @default.
- W4311573313 hasAuthorship W4311573313A5027475930 @default.